Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Probing the mechanism of reduced in vivo potency of insulin detemir171
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects71
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance68
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update57
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury55
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury46
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata40
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?37
Guidance for interactions between antiseizure medications35
Hormones, microbes, and PrEP drugs in the female genital tract33
Comorbidities and the right dose: antipsychotics31
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database30
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas29
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine27
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis27
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis27
Bioactivity descriptors for in vivo toxicity prediction: now and the future26
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals25
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer25
A comprehensive review of the efficacy and safety of ertugliflozin24
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study24
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update23
Correction23
0.099330902099609